Your search for non small cell lung cancer returned 19 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Diana Ernst, RPh remove

Your search for non small cell lung cancer returned 19 results

Sort Results:

Relevant Recent
News

Opdivo Plus Yervoy Approved for First-Line Treatment of Metastatic NSCLC

The FDA has approved the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
News

FDA Panel Votes on Ramucirumab for First-Line Treatment of Metastatic EGFR-Positive NSCLC

The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab (Cyramza; Lilly) plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). The vote was based on data from the phase 3 RELAY study (N=449), which evaluated…